Patients with bleeding disorders like hemophilia rely on life-saving clotting factors to keep their disease in check. These costly biologic treatments are produced by specialized pharmaceutical manufacturers.  Keeping track of these products can be a challenge since concentrate vials may have unit assay amounts that differ in small increments due to manufacturing variability, said David Aguero, Director of Medication Systems and Informatics at St. Jude Research Hospital.